Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

October 2022 | 106 pages | ID: A5C462C387FCEN
Global Markets Direct

Abstracts

Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Drugs In Development, 2022, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.

Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0 and Preclinical stages are 2, 14, 19, 1 and 5 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 3 molecules, respectively.

Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Anaplastic Astrocytoma - Overview
Anaplastic Astrocytoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anaplastic Astrocytoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anaplastic Astrocytoma - Companies Involved in Therapeutics Development
A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
Aettis Inc
AngioChem Inc
Apexigen Inc
Bayer AG
Berg LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Candel Therapeutics Inc
CDG Therapeutics Inc
Cellix Bio Pvt Ltd
Chimerix Inc
Cothera Bioscience Pty Ltd
Curis Inc
Everfront Biotech Inc
Fore Biotherapeutics Inc
Geneos Therapeutics Inc
Ipsen SA
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Merck KGaA
MimiVax LLC
Mustang Bio Inc
Nascent Biotech Inc
Novartis AG
OncoSynergy Inc
Orbus Therapeutics Inc
Orphelia Pharma SAS
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
PTC Therapeutics Inc
TheraBiologics Inc
Wayshine Biopharma Inc
Wuhan Binhui Biotechnology Co Ltd
Anaplastic Astrocytoma - Drug Profiles
afatinib dimaleate - Drug Profile
Product Description
Mechanism Of Action
aglatimagene besadenovec - Drug Profile
Product Description
Mechanism Of Action
BAY-1436032 - Drug Profile
Product Description
Mechanism Of Action
BAY-2666605 - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
CLXONC-643 - Drug Profile
Product Description
Mechanism Of Action
dabrafenib mesylate - Drug Profile
Product Description
Mechanism Of Action
eflornithine - Drug Profile
Product Description
Mechanism Of Action
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
FORE-8394 - Drug Profile
Product Description
Mechanism Of Action
futibatinib - Drug Profile
Product Description
Mechanism Of Action
G-207 - Drug Profile
Product Description
Mechanism Of Action
GENPV-001 - Drug Profile
Product Description
Mechanism Of Action
irinotecan hydrochloride - Drug Profile
Product Description
Mechanism Of Action
M-032 - Drug Profile
Product Description
Mechanism Of Action
MB-108 - Drug Profile
Product Description
Mechanism Of Action
MB-110 - Drug Profile
Product Description
Mechanism Of Action
OH-2 - Drug Profile
Product Description
Mechanism Of Action
ON-01 - Drug Profile
Product Description
Mechanism Of Action
ONC-206 - Drug Profile
Product Description
Mechanism Of Action
OS-2966 - Drug Profile
Product Description
Mechanism Of Action
P-28 - Drug Profile
Product Description
Mechanism Of Action
paclitaxel trevatide - Drug Profile
Product Description
Mechanism Of Action
palbociclib - Drug Profile
Product Description
Mechanism Of Action
paxalisib - Drug Profile
Product Description
Mechanism Of Action
pritumumab - Drug Profile
Product Description
Mechanism Of Action
regorafenib - Drug Profile
Product Description
Mechanism Of Action
ribociclib succinate - Drug Profile
Product Description
Mechanism Of Action
selinexor - Drug Profile
Product Description
Mechanism Of Action
SL-701 - Drug Profile
Product Description
Mechanism Of Action
sorafenib tosylate - Drug Profile
Product Description
Mechanism Of Action
sotigalimab - Drug Profile
Product Description
Mechanism Of Action
SurVaxM - Drug Profile
Product Description
Mechanism Of Action
TBX.OncV NSC - Drug Profile
Product Description
Mechanism Of Action
telaglenastat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
temozolomide - Drug Profile
Product Description
Mechanism Of Action
tepotinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
trotabresib - Drug Profile
Product Description
Mechanism Of Action
ubidecarenone - Drug Profile
Product Description
Mechanism Of Action
unesbulin - Drug Profile
Product Description
Mechanism Of Action
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
WSD-0922 - Drug Profile
Product Description
Mechanism Of Action
z-90099 - Drug Profile
Product Description
Mechanism Of Action
zotiraciclib citrate - Drug Profile
Product Description
Mechanism Of Action
Anaplastic Astrocytoma - Dormant Projects
Anaplastic Astrocytoma - Discontinued Products
Anaplastic Astrocytoma - Product Development Milestones
Featured News & Press Releases
Jan 19, 2022: Orbus Therapeutics’ phase 3 Eflornithine STELLAR study reaches full patient enrollment
Sep 28, 2021: Orbus Therapeutics granted European patent for method of use for Eflornithine
Mar 02, 2021: Orbus Therapeutics announces positive outcome of pre-planned interim futility analysis for phase 3 Eflornithine STELLAR study
Dec 23, 2020: Orbus Therapeutics receives U.S. Patent for Eflornithine formulations
Jul 10, 2020: Geneos Therapeutics announces first patient dosed with its DNA-based, neoantigen-targeting personalized vaccine technology
Feb 04, 2020: STELLAR clinical trial of eflornithine to enrol brain tumour patients
May 16, 2019: Adastra Pharmaceuticals announces that data from phase 1b clinical trial of Zotiraciclib will be presented at ASCO 2019
Jun 05, 2017: Orbus Therapeutics Announces ASCO Study Design Presentation of Pivotal Clinical Trial in Patients with Late-Stage Brain Cancer
Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Anaplastic Astrocytoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Anaplastic Astrocytoma - Dormant Projects, 2022
Anaplastic Astrocytoma - Dormant Projects, 2022 (Contd..1)
Anaplastic Astrocytoma - Dormant Projects, 2022 (Contd..2)
Anaplastic Astrocytoma - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Anaplastic Astrocytoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022